Deletion of Shp2 Tyrosine Phosphatase in Muscle Leads to Dilated Cardiomyopathy, Insulin Resistance, and Premature Death

REFERENCES

• Akazawa, H., and I. Komuro. 2003. Roles of cardiac transcription factors in cardiac hypertrophy. Circ. Res. 92:1079–1088.
   PubMed Web of Science ®Google Scholar
• Bard-Chapeau, E. A., J. Yuan, N. Droin, S. Long, E. E. Zhang, T. V. Nguyen, and G. S. Feng. 2006. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol. Cell. Biol. 26:4664–4674.
   PubMedGoogle Scholar
• Bruning, J. C., M. D. Michael, J. N. Winnay, T. Hayashi, D. Horsch, D. Accili, L. J. Goodyear, and C. R. Kahn. 1998. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2:559–569.
   PubMed Web of Science ®Google Scholar
• Camper-Kirby, D., S. Welch, A. Walker, I. Shiraishi, K. D. Setchell, E. Schaefer, J. Kajstura, P. Anversa, and M. A. Sussman. 2001. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ. Res. 88:1020–1027.
   PubMed Web of Science ®Google Scholar
• Carroll, R., A. N. Carley, J. R. Dyck, and D. L. Severson. 2005. Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts. Am. J. Physiol. Endocrinol. Metab. 288:E900–E906.
   PubMed Web of Science ®Google Scholar
• Case, R. D., E. Piccione, G. Wolf, A. M. Benett, R. J. Lechleider, B. G. Neel, and S. E. Shoelson. 1994. SH-PTP2/Syp SH2 domain binding specificity is defined by direct interactions with platelet-derived growth factor beta-receptor, epidermal growth factor receptor, and insulin receptor substrate-1-derived phosphopeptides. J. Biol. Chem. 269:10467–10474.
   PubMedGoogle Scholar
• Chien, K. R., K. U. Knowlton, H. Zhu, and S. Chien. 1991. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5:3037–3046.
   PubMed Web of Science ®Google Scholar
• Crackower, M. A., G. Y. Oudit, I. Kozieradzki, R. Sarao, H. Sun, T. Sasaki, E. Hirsch, A. Suzuki, T. Shioi, J. Irie-Sasaki, R. Sah, H. Y. Cheng, V. O. Rybin, G. Lembo, L. Fratta, A. J. Oliveira-dos-Santos, J. L. Benovic, C. R. Kahn, S. Izumo, S. F. Steinberg, M. P. Wymann, P. H. Backx, and J. M. Penninger. 2002. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110:737–749.
   PubMed Web of Science ®Google Scholar
• Donthi, R. V., G. Ye, C. Wu, D. A. McClain, A. J. Lange, and P. N. Epstein. 2004. Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity. J. Biol. Chem. 279:48085–48090.
   PubMedGoogle Scholar
• Dubois, M. J., S. Bergeron, H. J. Kim, L. Dombrowski, M. Perreault, B. Fournes, R. Faure, M. Olivier, N. Beauchemin, G. I. Shulman, K. A. Siminovitch, J. K. Kim, and A. Marette. 2006. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat. Med. 12:549–556.
   PubMedGoogle Scholar
• Graveleau, C., V. G. Zaha, A. Mohajer, R. R. Banerjee, N. Dudley-Rucker, C. M. Steppan, M. W. Rajala, P. E. Scherer, R. S. Ahima, M. A. Lazar, and E. D. Abel. 2005. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J. Biol. Chem. 280:31679–31685.
   PubMedGoogle Scholar
• Hagiwara, Y., S. Miyoshi, K. Fukuda, N. Nishiyama, Y. Ikegami, K. Tanimoto, M. Murata, E. Takahashi, K. Shimoda, T. Hirano, H. Mitamura, and S. Ogawa. 2007. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent I CaL, [Ca2+]i transient, and APD increase in cardiomyocytes. J. Mol. Cell Cardiol. 43:710–716.
   PubMed Web of Science ®Google Scholar
• Hardie, D. G. 2004. AMP-activated protein kinase: the guardian of cardiac energy status. J. Clin. Investig. 114:465–468.
   PubMed Web of Science ®Google Scholar
• Hawley, S. A., A. E. Gadalla, G. S. Olsen, and D. G. Hardie. 2002. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420–2425.
   PubMed Web of Science ®Google Scholar
• Hernandez, R., T. Teruel, and M. Lorenzo. 2001. Akt mediates insulin induction of glucose uptake and upregulation of GLUT4 gene expression in brown adipocytes. FEBS Lett. 494:225–231.
   PubMed Web of Science ®Google Scholar
• Hirota, H., J. Chen, U. A. Betz, K. Rajewsky, Y. Gu, J. Ross, Jr., W. Muller, and K. R. Chien. 1999. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97:189–198.
   PubMed Web of Science ®Google Scholar
• Johnatty, S. E., J. R. Dyck, L. H. Michael, E. N. Olson, and M. Abdellatif. 2000. Identification of genes regulated during mechanical load-induced cardiac hypertrophy. J. Mol. Cell Cardiol. 32:805–815.
   PubMed Web of Science ®Google Scholar
• Jougasaki, M., H. Leskinen, A. M. Larsen, A. Cataliotti, H. H. Chen, and J. C. Burnett, Jr. 2003. Leukemia inhibitory factor is augmented in the heart in experimental heart failure. Eur. J. Heart Fail. 5:137–145.
   PubMedGoogle Scholar
• Kacimi, R., and A. M. Gerdes. 2003. Alterations in G protein and MAP kinase signaling pathways during cardiac remodeling in hypertension and heart failure. Hypertension 41:968–977.
   PubMed Web of Science ®Google Scholar
• Kemppainen, J., H. Tsuchida, K. Stolen, H. Karlsson, M. Bjornholm, O. J. Heinonen, P. Nuutila, A. Krook, J. Knuuti, and J. R. Zierath. 2003. Insulin signalling and resistance in patients with chronic heart failure. J. Physiol. 550:305–315.
   PubMed Web of Science ®Google Scholar
• Kontaridis, M. I., K. D. Swanson, F. S. David, D. Barford, and B. G. Neel. 2006. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281:6785–6792.
   PubMed Web of Science ®Google Scholar
• Kontaridis, M. I., W. Yang, K. K. Bence, D. Cullen, B. Wang, N. Bodyak, Q. Ke, A. Hinek, P. M. Kang, R. Liao, and B. G. Neel. 2008. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation 117:1423–1435.
   PubMed Web of Science ®Google Scholar
• Kuhne, M. R., T. Pawson, G. E. Lienhard, and G. S. Feng. 1993. The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp. J. Biol. Chem. 268:11479–11481.
   PubMed Web of Science ®Google Scholar
• Kunisada, K., S. Negoro, E. Tone, M. Funamoto, T. Osugi, S. Yamada, M. Okabe, T. Kishimoto, and K. Yamauchi-Takihara. 2000. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl. Acad. Sci. USA 97:315–319.
   PubMed Web of Science ®Google Scholar
• Lai, L. A., C. Zhao, E. E. Zhang, and G. S. Feng. 2004. The Shp-2 tyrosine phosphatase, p. 275-299. In J. Arino and D. Alexander (ed.), Protein phosphatases, vol. 5. Springer-Verlag, Berlin, Germany.
   Google Scholar
• Maegawa, H., M. Hasegawa, S. Sugai, T. Obata, S. Ugi, K. Morino, K. Egawa, T. Fujita, T. Sakamoto, Y. Nishio, H. Kojima, M. Haneda, H. Yasuda, R. Kikkawa, and A. Kashiwagi. 1999. Expression of a dominant-negative SHP-2 in transgenic mice induces insulin resistance. J. Biol. Chem. 274:30236–30243.
   PubMed Web of Science ®Google Scholar
• Matsui, T., L. Li, J. C. Wu, S. A. Cook, T. Nagoshi, M. H. Picard, R. Liao, and A. Rosenzweig. 2002. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277:22896–22901.
   PubMed Web of Science ®Google Scholar
• Milarski, K. L., and A. R. Saltiel. 1994. Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. J. Biol. Chem. 269:21239–21243.
   PubMed Web of Science ®Google Scholar
• Minamisawa, S., Y. Sato, and M. C. Cho. 2004. Calcium cycling proteins in heart failure, cardiomyopathy and arrhythmias. Exp. Mol. Med. 36:193–203.
   PubMedGoogle Scholar
• Musi, N., N. Fujii, M. F. Hirshman, I. Ekberg, S. Froberg, O. Ljungqvist, A. Thorell, and L. J. Goodyear. 2001. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 50:921–927.
   PubMed Web of Science ®Google Scholar
• Myers, M. G., Jr., R. Mendez, P. Shi, J. H. Pierce, R. Rhoads, and M. F. White. 1998. The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling. J. Biol. Chem. 273:26908–26914.
   PubMed Web of Science ®Google Scholar
• Neel, B. G., H. Gu, and L. Pao. 2003. The ′Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28:284–293.
   PubMed Web of Science ®Google Scholar
• Nicol, R. L., N. Frey, G. Pearson, M. Cobb, J. Richardson, and E. N. Olson. 2001. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 20:2757–2767.
   PubMedGoogle Scholar
• Ozcelik, C., B. Erdmann, B. Pilz, N. Wettschureck, S. Britsch, N. Hubner, K. R. Chien, C. Birchmeier, and A. N. Garratt. 2002. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA 99:8880–8885.
   PubMed Web of Science ®Google Scholar
• Paternostro, G., D. Pagano, T. Gnecchi-Ruscone, R. S. Bonser, and P. G. Camici. 1999. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc. Res. 42:246–253.
   PubMed Web of Science ®Google Scholar
• Saxton, T. M., M. Henkemeyer, S. Gasca, R. Shen, D. J. Rossi, F. Shalaby, G. S. Feng, and T. Pawson. 1997. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 16:2352–2364.
   PubMed Web of Science ®Google Scholar
• Shai, S. Y., A. E. Harpf, C. J. Babbitt, M. C. Jordan, M. C. Fishbein, J. Chen, M. Omura, T. A. Leil, K. D. Becker, M. Jiang, D. J. Smith, S. R. Cherry, J. C. Loftus, and R. S. Ross. 2002. Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ. Res. 90:458–464.
   PubMed Web of Science ®Google Scholar
• Shioi, T., P. M. Kang, P. S. Douglas, J. Hampe, C. M. Yballe, J. Lawitts, L. C. Cantley, and S. Izumo. 2000. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19:2537–2548.
   PubMed Web of Science ®Google Scholar
• Standaert, M. L., G. Bandyopadhyay, L. Perez, D. Price, L. Galloway, A. Poklepovic, M. P. Sajan, V. Cenni, A. Sirri, J. Moscat, A. Toker, and R. V. Farese. 1999. Insulin activates protein kinases C-zeta and C-lambda by an autophosphorylation-dependent mechanism and stimulates their translocation to GLUT4 vesicles and other membrane fractions in rat adipocytes. J. Biol. Chem. 274:25308–25316.
   PubMed Web of Science ®Google Scholar
• Sugimoto, S., T. J. Wandless, S. E. Shoelson, B. G. Neel, and C. T. Walsh. 1994. Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. J. Biol. Chem. 269:13614–13622.
   PubMed Web of Science ®Google Scholar
• Tanaka, N., N. Dalton, L. Mao, H. A. Rockman, K. L. Peterson, K. R. Gottshall, J. J. Hunter, K. R. Chien, and J. Ross, Jr. 1996. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 94:1109–1117.
   PubMed Web of Science ®Google Scholar
• Tartaglia, M., E. L. Mehler, R. Goldberg, G. Zampino, H. G. Brunner, H. Kremer, I. van Der Burgt, A. H. Crosby, A. Ion, S. Jeffery, K. Kalidas, M. A. Patton, R. S. Kucherlapati, and B. D. Gelb. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29:465–468.
   PubMed Web of Science ®Google Scholar
• Wijesekara, N., D. Konrad, M. Eweida, C. Jefferies, N. Liadis, A. Giacca, M. Crackower, A. Suzuki, T. W. Mak, C. R. Kahn, A. Klip, and M. Woo. 2005. Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol. Cell. Biol. 25:1135–1145.
   PubMed Web of Science ®Google Scholar
• Wilkes, J. J., A. Hevener, and J. Olefsky. 2003. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 52:1904–1909.
   PubMed Web of Science ®Google Scholar
• Witteles, R. M., W. H. Tang, A. H. Jamali, J. W. Chu, G. M. Reaven, and M. B. Fowler. 2004. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J. Am. Coll. Cardiol. 44:78–81.
   PubMed Web of Science ®Google Scholar
• Zhang, E. E., E. Chapeau, K. Hagihara, and G. S. Feng. 2004. Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc. Natl. Acad. Sci. USA 101:16064–16069.
   PubMedGoogle Scholar
• Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear, and D. E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Investig. 108:1167–1174.
   PubMed Web of Science ®Google Scholar
• Zisman, A., O. D. Peroni, E. D. Abel, M. D. Michael, F. Mauvais-Jarvis, B. B. Lowell, J. F. Wojtaszewski, M. F. Hirshman, A. Virkamaki, L. J. Goodyear, C. R. Kahn, and B. B. Kahn. 2000. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 6:924–928.
   PubMed Web of Science ®Google Scholar